Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

31.48
Delayed Data
As of 4:14pm ET
 +0.18 / +0.58%
Today’s Change
29.39
Today|||52-Week Range
45.87
-17.48%
Year-to-Date
Mylan Down 24% Year to Date: What's Troubling the Stock?
Sep 20 / Zacks.com - Paid Partner Content
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?
Sep 11 / Zacks.com - Paid Partner Content
Biosimilar 2017 Progress Report: Stocks in Focus
Sep 14 / Zacks.com - Paid Partner Content
US pharma Gilead faces pricing dilemma with new cancer treatment
Aug 29 / FT.com - Paid Partner Content
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
Sep 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close31.30
Today’s open31.19
Day’s range31.13 - 31.94
Volume4,415,586
Average volume (3 months)6,165,682
Market cap$16.8B
Dividend yield--
Data as of 4:14pm ET, 09/25/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)-6.95%
Earnings growth (next 5 years)+3.21%
Revenue growth (last year)+17.44%
P/E ratio13.6
Price/Sales1.79
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-0.56-0.59%
PRGOPerrigo Company PLC+0.06+0.07%
JAZZJazz Pharmaceuticals...+1.60+1.08%
ALNYAlnylam Pharmaceutic...+3.24+2.85%
Data as of 4:02pm ET, 09/25/2017

Financials

Next reporting dateNovember 2, 2017
EPS forecast (this quarter)$1.20
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts